Sentynl Therapeutics, Inc. v. U.S. Specialty Insurance Co
-
March 09, 2022
Drugmaker's Opioid Probe Costs Not Covered, 9th Circ. Says
U.S. Specialty Insurance Co. has no obligation to cover more than $4 million in costs an opioid drugmaker said it incurred while responding to a U.S. Department of Justice investigation, the Ninth Circuit affirmed on Wednesday, citing a broad exclusion for claims relating to the company's products.
-
January 11, 2022
9th Circ. Skeptical Of Coverage For Co.'s Opioid Probe Costs
A Ninth Circuit panel seemed poised to secure U.S. Specialty Insurance Co.'s win in a coverage dispute with an opioid drugmaker seeking to recover $2.4 million it spent responding to government subpoenas, with one judge saying that the language of a key exclusion was broad but unambiguous.
-
September 17, 2021
Insurer Asks 9th Circ. To Affirm Opioid Coverage Dispute Win
U.S. Specialty Insurance Co. urged the Ninth Circuit on Friday to uphold a finding that a California pharmaceutical company wasn't entitled to coverage of costs it incurred as part of an investigation into the company's opioid drugs and marketing practices.
-
July 13, 2021
Pharma Co. Asks 9th Circ. To Revive Opioid Coverage Dispute
A California pharmaceutical company asked the Ninth Circuit to revive a directors and officers coverage dispute, saying its insurer misapplied a goods and products exclusion to avoid covering an investigation into the company's sales and marketing practices.